(BCG)	Bacillus Calmette-Guérin
(mUC)	metastatic urothelial cancer
(ICIs)	immune checkpoint inhibitors
(PD-1/PD-L1)	programmed cell death-1/programmed death ligand-1
(FDA)	Food and Drug Administration
(TURBT)	transurethral bladder tumor resection
(CTLA-4)	cytotoxic T-lymphocyte-associated-4
(IgV)	immunoglobulin V
(TCR)	T cell receptor
(TILs)	tumor-infiltrating lymphocytes
(EMA)	European Medicines Agency
(OS)	overall survival
(PFS)	progression-free survival
(ORR)	objective response rate
(MMAE)	monomethyl auristatin E
(EV)	enfortumab vedotin
(DOR)	diagnostic odds ratio
(TEAEs)	treatment-emergent adverse events
(MSI-H)	microsatellite instability-high
(dMMR)	mismatch repair deficiency